ADVERTISEMENT
Exclusive License for Wound Healing Technology
XCell Biologix (Kennesaw, GA) obtained the exclusive license to a new cell-free treatment chronic wounds and burns developed at the Wake Forest Institute for Regenerative Medicine (WFIRM; Winston-Salem, NC). The treatment is derived from the placental amnion and can be applied to the skin in a powder, liquid, or spray form, making it a valuable tool to protect, heal, and repair wounds by accelerating wound closure and promoting skin growth.
The worldwide licensing agreement allows XCell Biologix to further develop and commercialize the technology in severe burn and chronic wound markets. In the meantime, WFIRM will complete the initial phase of development as well as a potential small group clinical study.
Click here for more information.
Advertisement
Reimbursement Library From A to Z
Subscribe and never miss an article!
Advertisement
Coping With COVID-19
Advertisement